AttendMe Owl Logo
AttendMe
Sign In
All Pathways
Upper GI SurgeryDiagnostic

Esophageal Cancer Workup and Staging (NCCN 2024)

Esophageal Cancer Workup and Staging (NCCN 2024): Biopsy-Proven Esophageal Cancer → Staging Workup → Biomarker Testing → Clinical Stage → Superficial.

Pathway Overview

14 steps

Algorithm Steps

14 total

  1. 01Start

    Biopsy-Proven Esophageal Cancer

    Adenocarcinoma or SCC

  2. 02Action

    Staging Workup

    CT, PET-CT, EUS

    • CT C/A with contrast
    • PET-CT (especially SCC)
    • EUS for T/N staging
  3. 03Action

    Biomarker Testing

    HER2, PD-L1, MSI

    • HER2 (adenocarcinoma)
    • PD-L1 CPS score
    • MSI/dMMR status
  4. 04Decision

    Clinical Stage

    • Superficial (Tis-T1a)
    • Locoregional (T1b-T4a)
    • Locally advanced (T4b)
    • Metastatic (M1)
  5. Tis-T1a
  6. 05Action

    Superficial

    Tis-T1a, mucosa only

  7. 06Action

    Endoscopic Therapy

    EMR/ESD for Tis-T1a

    • Curative if no LVI, clear margins
    • Surveillance + Barrett's ablation
  8. 07End

    Surveillance & Support

    EGD q3-6mo x2yr, nutrition, follow-up imaging

  9. Non-curative EMR
  10. 08Action

    Esophagectomy

    Ivor Lewis, transhiatal, or McKeown

    • MIE preferred
    • R0 resection goal
    • Appropriate for T1b-T4a post-neoadjuvant
  11. Path rejoins step 07Shared downstream outcome
  12. T1b-T4a
  13. 09Action

    Locoregional

    T1b-T4a, resectable

  14. ≥T2 or N+
  15. 10Action

    Neoadjuvant Therapy

    CROSS chemoRT or FLOT

    • Carboplatin/paclitaxel + 41.4 Gy
    • FLOT for GEJ extension
  16. Path rejoins step 08Shared downstream outcome
  17. T1b, N0
  18. Path rejoins step 08Shared downstream outcome
  19. T4b
  20. 11Action

    Locally Advanced/T4b

    Unresectable or SCC organ preservation

  21. 12Action

    Definitive ChemoRT

    50-50.4 Gy concurrent chemo

    • Organ preservation for SCC
    • Salvage esophagectomy option
  22. Path rejoins step 07Shared downstream outcome
  23. M1
  24. 13Action

    Metastatic

    M1 disease

  25. 14Action

    Systemic Therapy

    Chemo + immunotherapy

    • FOLFOX/CAPOX + pembrolizumab
    • Trastuzumab if HER2+
    • Palliative stent for dysphagia
  26. Path rejoins step 07Shared downstream outcome

Guideline Source

NCCN Guidelines - Esophageal and GEJ Cancers Version 4.2024

DOI: 10.6004/jnccn.2024.0016View Guideline

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • GEJ tumors (Siewert I-III) have different classification
  • Cervical esophageal cancer typically definitive CRT
  • Fitness for esophagectomy requires careful evaluation

Applicable Regions

USAUUKEU

EU: ESMO esophageal cancer guidelines

UK: NICE oesophageal cancer pathway

US: NCCN esophageal guidelines

Version 1Next review: 2028-01-01

Related Upper GI Surgery Pathways

Bariatric Surgery Selection Criteria (ASMBS/IFSO 2024)

Diagnostic

Gastric Cancer Staging and Resection (NCCN 2024)

Management

Gastric Outlet Obstruction Management

Management

Post-Bariatric Surgery Complications Management

Management

Next steps

Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.

Calculator

Body Mass Index

Weight classification based on height and weight

Open page

Compare

AttendMe.ai vs UpToDate

See how this pathway workflow compares against UpToDate.

Open page

Commercial

Start free

Run the pathway in a live AttendMe account with citations and tracked usage.

Start free

Related Resources

All Clinical PathwaysClinical CalculatorsAI Chat with Auto-Detection

Frequently Asked Questions

What is the Esophageal Cancer Workup and Staging (NCCN 2024)?

The Esophageal Cancer Workup and Staging (NCCN 2024) is a diagnostic clinical algorithm for Upper GI Surgery. It provides a structured decision tree to guide clinical decision-making, based on NCCN Guidelines - Esophageal and GEJ Cancers Version 4.2024.

What guideline is the Esophageal Cancer Workup and Staging (NCCN 2024) based on?

This algorithm is based on NCCN Guidelines - Esophageal and GEJ Cancers Version 4.2024 (DOI: 10.6004/jnccn.2024.0016).

What are the limitations of the Esophageal Cancer Workup and Staging (NCCN 2024)?

Known limitations include: GEJ tumors (Siewert I-III) have different classification; Cervical esophageal cancer typically definitive CRT; Fitness for esophagectomy requires careful evaluation. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Esophageal Cancer Workup and Staging (NCCN 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free